HER2-Low Breast Cancer: Pathological and Clinical Landscape.

[1]  K. Nakagawa,et al.  [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification , 2019, International journal of cancer.

[2]  E. D. de Vries,et al.  A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. , 2019, Pharmacology & therapeutics.

[3]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  P. Parren,et al.  Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.

[5]  M. Piccart,et al.  Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review , 2019, Current Treatment Options in Oncology.

[6]  G. Peoples,et al.  Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. , 2019, Clinical immunology.

[7]  R. Greil,et al.  HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer , 2019, International journal of molecular sciences.

[8]  J. Cuzick,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Piccart,et al.  Treatment of advanced HER2-positive breast cancer: 2018 and beyond. , 2018, Cancer treatment reviews.

[12]  A. Schneeweiss,et al.  Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer , 2018, Investigational New Drugs.

[13]  G. Doherty,et al.  Activating HER2 mutations as emerging targets in multiple solid cancers , 2017, ESMO Open.

[14]  James T. Robinson,et al.  Variant Review with the Integrative Genomics Viewer. , 2017, Cancer research.

[15]  R. Weigel,et al.  A novel HER2 gene body enhancer contributes to HER2 expression , 2017, Oncogene.

[16]  Jinhua Dong,et al.  Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control , 2017, Scientific Reports.

[17]  G. Giaccone,et al.  First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Helene Dérand,et al.  A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2 , 2017, Modern Pathology.

[19]  J. Murray,et al.  Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence , 2016, Oncotarget.

[20]  J. Murray,et al.  Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Y. Kamata,et al.  Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. , 2015, Oncology reports.

[22]  John W. Adams,et al.  Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival , 2015, Breast Cancer Research.

[23]  E. Mittendorf,et al.  The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. , 2014, Immunotherapy.

[24]  E. Perez,et al.  Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer , 2014, Breast Cancer Research.

[25]  L. Xerri,et al.  SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases , 2013, BMC Cancer.

[26]  R. Ponzone,et al.  Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. , 2012, The oncologist.

[27]  P. Moore,et al.  Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties , 2011, Breast Cancer Research.

[28]  M. Espié,et al.  Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches , 2011, British Journal of Cancer.

[29]  C. Denkert,et al.  Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765) , 2011, Breast Cancer Research and Treatment.

[30]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[31]  C. Petropoulos,et al.  Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens , 2010, Pathology research international.

[32]  D. Rimm,et al.  Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.

[33]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[34]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Cairns,et al.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.

[36]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.